Table 2 Comparison of characteristics, PFT, BGA, laboratory tests and MDCT in patients with persistent respiratory symptoms and without any ongoing symptoms
Patients with long lasting respiratory COVID symptoms n = 78 | Patients without any long lasting COVID symptoms n = 39 | p-value | |
|---|---|---|---|
Days following acute COVID-19 | 76.5 [54; 93] | 90.0 [73; 120] | 0.019 |
Age | 46.99 ± 15.72 | 53.08 ± 15.22 | 0.048 |
Male (%) | 46.2% (36/78) | 59% (23/39) | 0.266 |
Hospitalisation in the past due to COVID 19 | 24.4% (19/78) | 23.1 (9/39) | 1.000 |
FVC (L) | 4.02 ± 1.08 | 4.29 ± 1.23 | 0.224 |
FVC (%) | 91.94 ± 15.66 | 99.46 ± 13.91 | 0.012 |
FVC < 80% | 19.2% (15/78) | 10.3 (4/39) | 0.330 |
TLC (L) | 6.11 ± 1.16 | 6.61 ± 1.36 | 0.044 |
TLC (%) | 99.19 ± 15.87 | 104.69 ± 12.73 | 0.062 |
TLC < LLN | 12.8% (10/78) | 2.6% (1/39) | 0.097 |
TLCO SB (%) | 79.87 ± 15.73 | 87.73 ± 17.50 | 0.016 |
TLCO SB < 80% | 42.3% (33/78) | 33.3% (13/39) | 0.462 |
TLCO/VA (%) | 92.75 ± 12.51 | 96.27 ± 16.74 | 0.203 |
TLCO/VA < 80% | 11.5% (9/78) | 15.4 (6/39) | 0.769 |
pO2 (mmHg) | 89.16 ± 9.98 | 88.78 ± 8.90 | 0.841 |
pCO2 (mmHg) | 37.92 ± 3.85 | 39.24 ± 3.67 | 0.078 |
pCO2 < 35 mmHg | 19.2% (15/78) | 12.8% (5/39) | 0.543 |
Fibrinogen (mg/dl) | 322.19 ± 88.76 | 327.82 ± 71.91 | 0.732 |
Fibrinogen > 400 mg/dl | 17.9 (14/78) | 10.3 (4/39) | 0.415 |
IL-6 (pg/ml)* | 1.50 [1.50, 2.36] | 1.61 [1.50, 2.28] | 0.708 |
IL-6 ≥ 7 pg/ml | 3.8% (3/78) | 5.1% (2/39) | 1.000 |
CRP (mg/dl)* | 0.11 [0.05, 0.24] | 0.12 [0.06, 0.19] | 0.824 |
CRP > 0.5 mg/dl | 14.1% (11/78) | 10.3% (4/39) | 0.771 |
D-dimer (µg/ml)* | 0.29 [0.27, 0.36] | 0.28 [0.27, 0.50] | 0.358 |
D-dimer > 0.5 µg/ml | 11.5% (9/78) | 25.6% (10/39) | |
Ground glass opacities/consolidation/pulmonary embolism in CT | 38.5% (30/78) | 28.2% (11/39) | 0.448 |